Biomoda, Inc. Out sources to Seattle's PhenoPath for Cancer Diagnostic Development

PhenoPath contract part of multi-step plan to collaborate with established diagnostic organizations

Biomoda, Inc. has contracted with PhenoPath Laboratories, PLLC, www.phenopath.com a research and development pathology laboratory in Seattle, Washington.  PhenoPath will support Biomoda’s diagnostic development program for early detection and treatment of cancers, primarily lung cancer. Phenopath is a widely respected and highly experienced laboratory organization with particular skills and expertise in pathology and biomarker development and applications.

In the past eight months Biomoda has entered into numerous relationships in order to expedite and further perfect its patented and proprietary developments for regulatory approval, accelerated commercialization and market acceptance. Among these organizations with whom Biomoda is working are: Esocor LLC, JR Associates, Majestic Sarl, Triangulum Consulting Services, Inc. and TriCore Reference Laboratories. PhenoPath Laboratories, PLLC is a significant element to this strategy.

Biomoda, Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The Company, exclusive worldwide licensee from the University of California of several patents developed for noninvasive early detection and treatment of lung cancer, is in the process of registering additional patents in this area.   The Company’s proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products.  Operating from its laboratory situated at Kirtland Air Force Base (Albuquerque, NM), the Company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next sixty days.   

* * * * *

This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words “believes,” “anticipates,” “expects,” “estimates,” and words of similar import. The Company’s actual results could differ materially from any forward-looking statements, which reflect management’s opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The Company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the Company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. For additional information, visit the Biomoda web site at www.biomoda.com or call us at 505-821-0875.